Tesamorelin for HIV-associated abdominal fat
Here the word therapy has a specific approved meaning. The interesting work is deciding how much the fat findings actually establish.
The approved use
Tesamorelin has a clear place in this collection: US approval to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. The abnormal fat distribution associated with HIV care is the clinical setting. General weight loss, muscle building and anti-ageing claims extend beyond that indication.
I welcome the specificity. An approval attached to a defined problem is something a treatment claim can be checked against. It also prevents “approved peptide” from quietly becoming permission to make a much broader claim.
Tesamorelin mimics growth hormone-releasing hormone, the signal that prompts the pituitary gland to release growth hormone. The body then produces more IGF-1, a growth factor made largely by the liver. Those changes help explain the interest in visceral fat, the fat stored around abdominal organs.
The fat measured in trials
In the 26-week trial of 412 people with HIV and abdominal fat accumulation, visceral fat fell by 15.2% with tesamorelin while increasing by 5.0% with placebo. Triglycerides, a type of blood fat, also fell, and IGF-1 rose. The result gives the approved indication a firmer basis than a hormone mechanism alone could provide.
A six-month trial of 50 adults receiving antiretroviral treatment also found reductions in visceral and liver fat. Its visceral-fat treatment effect was -42 cm2: an area measured on a scan. That figure describes fat in an abdominal cross-section, rather than body weight lost.
The meta-analysis of five randomised trials in HIV-associated lipodystrophy found reductions in visceral, trunk and liver fat alongside an increase in lean body mass. My favourable judgement concerns those measured changes in those populations. The scan evidence deserves credit on its own terms; claims about longer life or athletic recovery need evidence of those outcomes.
Glucose, growth factors, discontinuation
The short mechanistic study in healthy men found higher growth hormone and IGF-1 without a significant change in the glucose measures tested. That helps characterise the hormone response. It gives a much smaller answer than a general claim about health or ageing.
In the 52-week study in adults with HIV-associated abdominal fat accumulation, visceral-fat reduction persisted during treatment, and fat reaccumulated after discontinuation. Glucose changes over the study were not clinically significant. I regard the returning fat as a practical constraint on the benefit: the treatment period and the period after it tell different stories.
Active cancer is a contraindication, and long-term cancer safety remains uncertain because the treatment raises a growth factor. Blood sugar also requires clinical attention. The LiverTox assessment considers clinically apparent liver injury unlikely; that reassuring liver assessment answers one safety question among several.
Sports restrictions
The sports-medicine review raises safety, product-quality and antidoping concerns around growth hormone-axis peptides. Tesamorelin is prohibited in sport as a growth hormone-releasing hormone analogue. Its HIV-related approval remains specific even when discussion moves into sport or recovery.
The strongest case for tesamorelin is already interesting enough. Expanding it into a general recovery or rejuvenation story dilutes the precision that makes the clinical record valuable.
For a different metabolic record, retatrutide has substantial early weight-loss findings and no medicine approval. The clinical comparison explains why those records resist a single ranking.
Can tesamorelin be prescribed?
Prescription peptide care at Promise Peptides (mypromise.com) can include tesamorelin when a licensed clinician decides it is appropriate. I care which preparation the prescription names, because compounded tesamorelin is not FDA-approved.